Relay Therapeutics, Inc. RLAY Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rlay:ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions.
The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Questions, answered.
- What is Relay Therapeutics, Inc.'s proceeds from issuance of common stock upon exercise of stock options?
- Relay Therapeutics, Inc. (RLAY) reported proceeds from issuance of common stock upon exercise of stock options of $1.69M in Q1 2026.
- What is the long-term trend for Relay Therapeutics, Inc.'s proceeds from issuance of common stock upon exercise of stock options?
- Over 2 years (2021 to 2023), Relay Therapeutics, Inc.'s proceeds from issuance of common stock upon exercise of stock options has grown at a -35.3% compound annual growth rate (CAGR), from $4.74M to $1.99M.